# Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma

> **NCT06959979** · EARLY_PHASE1 · RECRUITING · sponsor: **Fondazione Policlinico Universitario Agostino Gemelli IRCCS** · enrollment: 60 (estimated)

## Conditions studied

- Medulloblastoma, Childhood

## Interventions

- **DRUG:** CDK4/6 Inhibitor (Palbociclib, Ribociclib, Abemaciclib)

## Key facts

- **NCT ID:** NCT06959979
- **Lead sponsor:** Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-25
- **Primary completion:** 2026-08-31
- **Final completion:** 2026-08-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-05-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06959979

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06959979, "Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06959979. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*